Frontiers in Cardiovascular Medicine (Dec 2023)

Superfamily II helicases: the potential therapeutic target for cardiovascular diseases

  • Tianxiang Fang,
  • Tianxiang Fang,
  • Tianxiang Fang,
  • Tianxiang Fang,
  • Xizhi Wang,
  • Ning Huangfu,
  • Ning Huangfu,
  • Ning Huangfu

DOI
https://doi.org/10.3389/fcvm.2023.1309491
Journal volume & issue
Vol. 10

Abstract

Read online

Cardiovascular diseases (CVDs) still maintain high morbidity and mortality globally. Helicases, a unique class of enzymes, are extensively implicated in the processes of nucleic acid (NA) metabolism across various organisms. They play a pivotal role in gene expression, inflammatory response, lipid metabolism, and so forth. However, abnormal helicase expression has been associated with immune response, cancer, and intellectual disability in humans. Superfamily II (SFII) is one of the largest and most diverse of the helicase superfamilies. Increasing evidence has implicated SFⅡ helicases in the pathogenesis of multiple CVDs. In this review, we comprehensively review the regulation mechanism of SFⅡ helicases in CVDs including atherosclerosis, myocardial infarction, cardiomyopathies, and heart failure, which will contribute to the investigation of ideal therapeutic targets for CVDs.

Keywords